Pituitary radiotherapy for Cushing's disease. 2010

Marco Losa, and Piero Picozzi, and Maria Grazia Redaelli, and Andrea Laurenzi, and Pietro Mortini
Department of Neurosurgery, Istituto Scientifico San Raffaele, Università Vita-Salute, Milano, Italy. losa.marco@hsr.it

BACKGROUND The treatment of choice for Cushing's disease is pituitary surgery. Second-line treatments include repeat pituitary surgery, radiation therapy, medical therapy, and bilateral adrenalectomy. The most used modalities to irradiate patients with Cushing's disease include fractionated radiotherapy and single-dose Gamma Knife. We aim to review the efficacy and safety of radiotherapy in patients with persistent or recurring Cushing's disease. RESULTS Remission of Cushing's disease after radiotherapy ranges from 42 to 83%. There seems to be no clear difference according to the technique of radiation used. Most patients experience remission of disease within 3 years from treatment, with only few cases reaching normal cortisol secretion after a longer follow-up. Control of tumor growth varies from 93 to 100%. Severe side effects of radiotherapy, such as optic neuropathy and radionecrosis, are uncommon. New-onset hypopituitarism is the most frequent side effect of radiation, occurring in 30-50% of patients treated by fractionated radiotherapy while it has been reported in 11-22% of patients after Gamma Knife. CONCLUSIONS Radiotherapy is an effective second-line treatment in patients with Cushing's disease not cured by surgery. Consideration of the advantages and disadvantages of radiotherapy in comparison with other therapeutic options should always be carried out in the single patient before deciding the second-line therapeutic strategy for persisting or recurring Cushing's disease.

UI MeSH Term Description Entries
D010911 Pituitary Neoplasms Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA. Pituitary Cancer,Cancer of Pituitary,Cancer of the Pituitary,Pituitary Adenoma,Pituitary Carcinoma,Pituitary Tumors,Adenoma, Pituitary,Adenomas, Pituitary,Cancer, Pituitary,Cancers, Pituitary,Carcinoma, Pituitary,Carcinomas, Pituitary,Neoplasm, Pituitary,Neoplasms, Pituitary,Pituitary Adenomas,Pituitary Cancers,Pituitary Carcinomas,Pituitary Neoplasm,Pituitary Tumor,Tumor, Pituitary,Tumors, Pituitary
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000236 Adenoma A benign epithelial tumor with a glandular organization. Adenoma, Basal Cell,Adenoma, Follicular,Adenoma, Microcystic,Adenoma, Monomorphic,Adenoma, Papillary,Adenoma, Trabecular,Adenomas,Adenomas, Basal Cell,Adenomas, Follicular,Adenomas, Microcystic,Adenomas, Monomorphic,Adenomas, Papillary,Adenomas, Trabecular,Basal Cell Adenoma,Basal Cell Adenomas,Follicular Adenoma,Follicular Adenomas,Microcystic Adenoma,Microcystic Adenomas,Monomorphic Adenoma,Monomorphic Adenomas,Papillary Adenoma,Papillary Adenomas,Trabecular Adenoma,Trabecular Adenomas
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D047748 Pituitary ACTH Hypersecretion A disease of the PITUITARY GLAND characterized by the excess amount of ADRENOCORTICOTROPIC HORMONE secreted. This leads to hypersecretion of cortisol (HYDROCORTISONE) by the ADRENAL GLANDS resulting in CUSHING SYNDROME. Cushing Disease,Cushing's Disease,Inappropriate ACTH Secretion Syndrome,Inappropriate Adrenocorticotropic Hormone Secretion,Adrenocorticotropic Hormone, Inappropriate Secretion,Cushing Disease, Pituitary,Pituitary Cushing Syndrome,Pituitary-Dependant Cushing Syndrome,Pituitary-Dependant Hypercortisolism,Pituitary-Dependant Hypercortisolism Disorder,Cushing Syndrome, Pituitary,Cushing Syndrome, Pituitary-Dependant,Disease, Cushing,Hypercortisolism Disorder, Pituitary-Dependant,Hypercortisolism, Pituitary-Dependant,Hypersecretion, Pituitary ACTH,Pituitary Cushing Disease,Pituitary Dependant Cushing Syndrome,Pituitary Dependant Hypercortisolism,Pituitary Dependant Hypercortisolism Disorder,Pituitary-Dependant Hypercortisolism Disorders,Pituitary-Dependant Hypercortisolisms

Related Publications

Marco Losa, and Piero Picozzi, and Maria Grazia Redaelli, and Andrea Laurenzi, and Pietro Mortini
January 1993, Clinical oncology (Royal College of Radiologists (Great Britain)),
Marco Losa, and Piero Picozzi, and Maria Grazia Redaelli, and Andrea Laurenzi, and Pietro Mortini
March 2009, Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion,
Marco Losa, and Piero Picozzi, and Maria Grazia Redaelli, and Andrea Laurenzi, and Pietro Mortini
January 1935, Proceedings of the Royal Society of Medicine,
Marco Losa, and Piero Picozzi, and Maria Grazia Redaelli, and Andrea Laurenzi, and Pietro Mortini
November 2021, Acta neurochirurgica,
Marco Losa, and Piero Picozzi, and Maria Grazia Redaelli, and Andrea Laurenzi, and Pietro Mortini
January 2010, Neuroendocrinology,
Marco Losa, and Piero Picozzi, and Maria Grazia Redaelli, and Andrea Laurenzi, and Pietro Mortini
January 1979, Nihon rinsho. Japanese journal of clinical medicine,
Marco Losa, and Piero Picozzi, and Maria Grazia Redaelli, and Andrea Laurenzi, and Pietro Mortini
January 2018, Frontiers in endocrinology,
Marco Losa, and Piero Picozzi, and Maria Grazia Redaelli, and Andrea Laurenzi, and Pietro Mortini
November 2007, Arquivos brasileiros de endocrinologia e metabologia,
Marco Losa, and Piero Picozzi, and Maria Grazia Redaelli, and Andrea Laurenzi, and Pietro Mortini
January 1994, Current therapy in endocrinology and metabolism,
Marco Losa, and Piero Picozzi, and Maria Grazia Redaelli, and Andrea Laurenzi, and Pietro Mortini
April 1977, British medical journal,
Copied contents to your clipboard!